Biotech Values

[ilpapa]

DVAX seems to think Heplisav is approvable, but this may be whistling past the graveyard.

BERKELEY, CA--(Marketwire -05/08/12)- Dynavax Technologies Corporation (DVAX) announced today, that following the recent submission of the U.S. Biologics License Application (BLA) to the Food and Drug Administration (FDA), it intends to begin developing a commercial operation capable of independently launching HEPLISAV™ in the U.S. The Company believes that being able to bring HEPLISAV to the market successfully will ultimately help maximize long-term value for its shareholders.